Sensus Healthcare, Inc. reported a significant decline in financial performance for the fiscal year ending December 31, 2025, with revenues of $27.5 million, a decrease of 34% from $41.8 million in 2024. The company experienced a net loss of $7.7 million, compared to a net income of $6.6 million in the previous year. This downturn was primarily attributed to reduced sales to its largest customer, which accounted for 52% of revenues in 2025, down from 73% in 2024. The decrease in unit sales, which fell to 70 from 115, also contributed to the revenue decline.
In terms of operational changes, Sensus Healthcare formed a new subsidiary, Sensus Healthcare Services, LLC, in February 2024, aimed at providing operational healthcare services to dermatology clinics. The company also launched the Sensus Healthcare Financial Services program in February 2026, designed to facilitate the acquisition of its systems through flexible financing options. Additionally, the introduction of new reimbursement codes by CMS, effective January 1, 2026, is expected to enhance demand for Sensus's products, although uncertainties remain regarding customer demand and inflationary pressures.
The company reported a gross profit of $11.9 million in 2025, representing 43.3% of revenue, down from 58.4% in 2024. Operating expenses increased to $22.2 million, driven by higher selling and marketing costs, which rose by 30% to $6.5 million, and research and development expenses, which surged by 86% to $7.8 million due to lobbying costs related to reimbursement codes and increased product development efforts. The company anticipates that research and development expenses will decrease significantly in 2026.
Sensus Healthcare's operational metrics indicate a decrease in accounts receivable, which fell by 70% to $6.0 million, reflecting lower sales. Conversely, inventory levels increased by 44% to $14.6 million, as the company prepared for anticipated future sales. The company maintained a stable cash position, with cash and cash equivalents at $22.1 million, unchanged from the previous year. As of December 31, 2025, Sensus employed 60 individuals, with no labor unions involved.
Looking ahead, Sensus Healthcare aims to return to profitability in 2026 by increasing sales and managing operational expenses. The company is optimistic about the potential impact of the new reimbursement codes on product demand, although it acknowledges challenges such as inflation and reliance on a concentrated customer base. The company’s ability to navigate these uncertainties will be critical to its financial recovery and growth in the coming year.
About Sensus Healthcare, Inc.
Sensus Healthcare develops non-invasive, cost-effective superficial radiation therapy (SRT) devices for treating skin conditions like non-melanoma skin cancer and keloids. Its products serve dermatology and radiation oncology markets worldwide, offering safe, effective alternatives to surgery and traditional radiation. The company emphasizes proprietary technology, regulatory compliance, and global distribution, focusing on clinical outcomes, ease of use, and expanding aesthetic and medical applications.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.